


PHARMACEUTICAL 2017



Catalent Inc. Rank 16 of 313





PHARMACEUTICAL 2017



Catalent Inc. Rank 16 of 313

The relative strengths and weaknesses of Catalent Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Catalent Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 473% points. The greatest weakness of Catalent Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 217% points.

The company's Economic Capital Ratio, given in the ranking table, is 181%, being 598% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	790,200
Cost of Goods Sold	0
Intangible Assets	1,290,500
Liabilities, Current	391,200
Liabilities, Non-Current	0
Other Assets	104,600
Other Compr. Net Income	-131,400
Other Expenses	1,303,200
Other Liabilities	0
Other Net Income	-75,600
Property and Equipment	905,800
Research and Development	0
Revenues	1,848,100
Selling, General and Administrative Expense	358,100

Output Variable	Value in 1000 USD
Assets	3,091,100
Liabilities	391,200
Expenses	1,661,300
Stockholders Equity	2,699,900
Net Income	111,200
Comprehensive Net Income	45,500
Economic Capital Ratio	181%